
Please try another search
By Samuel Indyk
Investing.com – Shares in UK pharmaceutical company GlaxoSmithKline (LON:GSK) surged higher on Thursday after the Financial Times reported that activist hedge fund Elliott Management has built up a stake in the company.
The stake is said to be “multibillion-pounds” in size and is a “significant” position for the firm.
GSK has been developing a Covid-19 vaccine with French pharmaceutical giant Sanofi (PA:SASY) but, after a dosing mishap, the two companies had to redo an early-stage trial of the jab. The setback put GSK miles behind its peers, with AstraZeneca (NASDAQ:AZN), Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Moderna (NASDAQ:MRNA) all providing Covid-19 vaccinations across the globe.
As the FT points out, since GSK CEO Dame Emma Walmsley took the reins in April 2017, the GSK share price has fallen 14%. During the same timeframe, AstraZeneca shares are up 49% and Pfizer is up 16%.
Back in February, GSK confirmed that plans to split its Biopharmaceutical division and Healthcare business into two separate entities was on track for next year.
“Two businesses with a sharper focus should be more efficient than one conglomerate, and it will help reduce the confusion around exactly what GSK is offering investors,” said Hargreaves Lansdown analyst Nicholas Hyett in February. “But it also means investors are buying into what will one day be two radically different businesses.”
It is unclear at the moment what Elliott Management’s plans are for the business but they could include plans to ouster CEO Walmsley or an attempt to stop the company from splitting the two units.
At 13:05BST, GlaxoSmithKline shares were trading higher by 6.2% at £13.70.
By Sam Boughedda Michael Burry, the investor made famous by the movie "The Big Short," and the founder of Scion Asset Management, said in a tweet Monday that the "Bullwhip Effect"...
By Sam Boughedda In a research note Monday, Morgan Stanley equity strategist Sheena Shah, writing about the crypto market, said GPU demand should slow as the second-largest crypto...
Epizyme Inc (NASDAQ: EPZM) shares are trading higher Monday after the company announced it entered into a definitive agreement to be acquired by Ipsen. "We expect that this...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.